Cellectis Romainvil (CMVLF) 32.1900 $CMVLF Cellectis to

New Post Public Reply Private Reply Replies (0) Message Board
Stock_Tracker
Cellectis Romainvil (CMVLF) 32.1900 $CMVLF

Cellectis to Present Data on Genome Engineering for Adoptive Immunotherapy at the American Society of Clinical Oncology Annual Meeting
Business Wire - Wed May 13, 5:00PM CDT
Regulatory News:
CLLS: 32.25 (+0.86)

Cellectis S.A. to Present Data on its Allogeneic CAR T Cell Programs at American Society of Gene & Cell Therapy Annual Meeting
Business Wire - Thu May 07, 5:00PM CDT
Regulatory News:
CLLS: 32.25 (+0.86)

Cellectis Plant Sciences Becomes Calyxt
Business Wire - Mon May 04, 5:05PM CDT
Cellectis plant sciences, Inc., a Minnesota-based Company focusing on developing healthier food products, announced today that it has changed its corporate name to Calyxt, Inc. The company will use this new name as of today.

Cellectis S.A. Announces Calyxt is New Name for Its Plant Sciences Subsidiary
Business Wire - Mon May 04, 5:00PM CDT
Regulatory News:
CLLS: 32.25 (+0.86)

Cellectis Plant Sciences, Inc. Locks Early CRISPR Intellectual Property Uses in Plants
Business Wire - Wed Apr 15, 5:02PM CDT
Regulatory News:

Cellectis Plant Sciences, Inc. Publishes a Study Demonstrating Reduced Acrylamide in Fried Potatoes
Business Wire - Tue Apr 14, 5:14PM CDT
Regulatory News:

Cellectis Announces Presentations at Upcoming Conferences
Business Wire - Thu Apr 09, 5:24PM CDT
Regulatory News:
CLLS: 32.25 (+0.86)

Cellectis Opens Labs and Offices in Manhattan, New York
Business Wire - Wed Apr 08, 5:17PM CDT
Regulatory News:
CLLS: 32.25 (+0.86)

Citi Appointed Depositary Bank for Cellectis' ADR Programme
Business Wire - Wed Apr 08, 6:44AM CDT
Citi, acting through Citibank N.A., has been appointed by Cellectis S.A. ("Cellectis", a gene-editing company, as depositary bank for their Level 3 American Depositary Receipt (ADR) programme listed on Nasdaq Global Market, which trades under symbol "CLLS". Each ordinary share is equivalent to 1 ADR. Cellectis' ordinary shares are listed on Alternext Paris and trade under symbol "ALCLS".
C: 54.24 (-0.36)

Cellectis Prices Initial Public Offering of American Depositary Shares
Business Wire - Tue Mar 24, 8:29PM CDT
Regulatory News:

Medigene AG: Addressing The CAR-T Market Pain Points
Decision Analytics - Seeking Alpha - Wed Mar 18, 11:51AM CDT
I have written about the market opportunity for adoptive cancer immunotherapy before when my interest was piqued by the incredible appreciation of a number of early-stage CAR-T therapy companies (a form of adoptive immunotherapy). Companies such as...
MDVN: 122.90 (-0.47), JNJ: 102.30 (+0.47), ZIOP: 9.17 (-0.17), BLCM: 23.02 (-1.37), KITE: 50.02 (-2.24), JUNO: 43.37 (-1.52), NVS: 103.75 (-0.15)

Cellectis: Finding Value In A Crowded CAR-T Space
Bay Area Biotech - at Seeking Alpha - Tue Mar 10, 8:51PM CDT
Chimeric Antigen Receptor (CAR)-engineered T-cells are an exciting, emerging new space in cancer therapy. At recent American Society of Hematology (ASH) annual meetings, the CAR presentations were met with the most fanfare, attention,...
BLUE: 154.42 (-2.98), ZIOP: 9.17 (-0.17), PFE: 33.99 (+0.05), XON: 40.08 (-0.90), AMGN: 162.36 (+0.38), GSK: 44.77 (-0.22), IMUC: 0.48 (+0.01), CELG: 115.53 (+0.45), JNJ: 102.30 (+0.47), BLCM: 23.02 (-1.37), KITE: 50.02 (-2.24), JUNO: 43.37 (-1.52), NVS: 103.75 (-0.15)

Cellectis SA Shareholders General Meeting of February 16, 2015
Business Wire - Tue Feb 17, 12:26PM CST
Regulatory News:

Not For The Faint Of CAR-T: The CAR-T Landscape In Early 2015
EP Vantage - Seeking Alpha - Fri Feb 06, 1:26PM CST
This is an extract from a longer report. If you followed last year's explosion of enthusiasm in CAR therapies you might have assumed that this was a super-novel approach that had just burst onto the scientific stage. In fact work on the synthetic...
BLUE: 154.42 (-2.98), CLRB: 2.74 (+0.08), BLCM: 23.02 (-1.37), KITE: 50.02 (-2.24), JUNO: 43.37 (-1.52), NVS: 103.75 (-0.15)

CAR-T Vs ErbB3 Market Opportunity Comparison
Decision Analytics - Seeking Alpha - Wed Jan 21, 12:32PM CST
CAR-T therapy, also known as "Adoptive Immunotherapy", has been the result of significant investor excitement recently. One look at the stock charts for JUNO and KITE is illustrative of this optimism. While this enthusiasm may be warranted,...
MACK: 12.66 (+0.34), BLUE: 154.42 (-2.98), ZIOP: 9.17 (-0.17), BLCM: 23.02 (-1.37), KITE: 50.02 (-2.24), AVEO: 1.19 (-0.04), JUNO: 43.37 (-1.52), GSK: 44.77 (-0.22), REGN: 489.01 (-2.42), NVS: 103.75 (-0.15)

Kite Pharma/Amgen: A Strong Combination
Henry Wolfe - at Seeking Alpha - Thu Jan 15, 12:19PM CST

ZIOP: 9.17 (-0.17), BLCM: 23.02 (-1.37), KITE: 50.02 (-2.24), AMGN: 162.36 (+0.38), JUNO: 43.37 (-1.52)

Cellectis and Ohio State University, Through the Ohio State Innovation Foundation, Enter Into Licensing Agreement for Chimeric Antigen Receptor Technology Targeting Multiple Myeloma
Business Wire - Tue Jan 13, 12:30AM CST
Regulatory News:

Cellectis Plans to Conduct Registered Initial Public Offering in the U.S.
Business Wire - Thu Jan 08, 12:17PM CST
Regulatory News:

Cellectis Announces the Issuance by the USPTO of a Patent Covering a Seminal Nuclease-Based "gene editing" Method
Business Wire - Tue Jan 06, 11:30AM CST
Regulatory News:

Cellectis Is Late To The CAR-T Cell Race, But Could Finish First
Intrepid Investor - at Seeking Alpha - Fri Jan 02, 3:21PM CST

BLUE: 154.42 (-2.98), BLCM: 23.02 (-1.37), KITE: 50.02 (-2.24), JUNO: 43.37 (-1.52), GSK: 44.77 (-0.22), NVS: 103.75 (-0.15), CELG: 115.53 (+0.45)

Scroll down for more posts ▼

Top 10 Most Recent News Articles

BIBIBOP Brings Good Vibes with OLIPOP Happy Hour

Updated Category News Views 131

Boosting Midday Energy with BIBIBOP's New Promo Here we go, folks. BIBIBOP Asian Grill is dialing up the culinary energy just when you need it most. From November 16 to 22, during their Good Energy Happy Hour, they’re serving up a deal designed to pump some pep into your afternoon—free OLIPOP prebiotic soda with any regular bowl purchase. Just stroll into any of their...

Continue Reading
Maritime Safety Urged After New Orleans Vessel Incident

Updated Category News Views 97

The Mississippi River saw a bit of drama near the Port of New Orleans when a river cruise turned into an unexpected rescue operation. Listen up, because incidents like this bring maritime safety right to the forefront; we can't ignore the waters that shape our daily lives here in the Big Easy. Navigating the Waters Safely Some 150 souls found themselves in a pickle when...

Continue Reading
Koppers Faces SEC Scrutiny After Earnings Miss

Updated Category News Views 169

Koppers' Third-Quarter Blues: Missing the Mark Koppers Holdings Inc. (NYSE: KOP) took a hard hit this quarter, missing Wall Street's earnings expectations by a mile. The adjusted earnings per share came in at just $0.77, while the suits down on Wall Street were expecting something closer to $1.34 to $1.37. Now, if you’re holding KOP in your portfolio, you're probably...

Continue Reading
Cardinal Infrastructure Faces Legal Scrutiny Amid Losses

Updated Category News Views 125

Cardinal Infrastructure Group Under Intense Investor Scrutiny Well, ain't this a messy soup of financial blunders? Cardinal Infrastructure Group (Nasdaq: CDNL) finds itself on the sharp end of a potential securities law investigation, thanks to some colossal screw-ups in managing project costs and estimates. Investors are rightly pissed after the company's shares...

Continue Reading
Biointron's RushDATA™: Speeding Up Antibody Discovery

Updated Category News Views 227

A New Chapter in Antibody Discovery Well, color me intrigued. Biointron, a name you'd recognize if you've got even a toe in the biotech pond, just threw a serious curveball into the antibody discovery game with RushDATA™—an AI- and machine learning-driven platform that's packing a punch. And it's not just about throwing tech buzzwords around; this thing clocks...

Continue Reading
Will Hair Loss Drugs Challenge Transplant Clinics?

Updated Category News Views 73

Emerging Treatments Stir Up Hair Loss Scene You ever get the feeling we're on the brink of something big? That's where we are with hair loss treatments, folks. As of late 2026, new drugs are making waves in clinical trials, but they’re not yet giving hair transplant clinics any sleepless nights. Smile Hair Clinic's co-founders, Dr. Mehmet Erdo?an and Dr. Gökay Bilgin,...

Continue Reading
LaserAway Expands to 244 Clinics Over 20 Years

Updated Category News Views 137

A Milestone in Aesthetic Dermatology Twenty years, folks. That's a long haul for most businesses, let alone one in the fickle field of aesthetic dermatology. LaserAway, the juggernaut in this arena, has just opened its 244th clinic at 6300 Kingery Hwy in Willowbrook, IL. Nothing to be sneezed at. Imagine running a business, let alone one that's been amping up aesthetic...

Continue Reading
MV Transportation Celebrates Leadership Nomination for FTA

Updated Category News Views 108

MV Throws Support Behind Aesch for FTA Role In this wild world where public transit feels the heat from financial burdens, MV Transportation's recent move to support Mark Aesch for the Federal Transit Administration's top spot isn’t just a nod of approval—it's a full-blown trumpet blast. They're not just doling out a basic endorsement here; they're practically waving...

Continue Reading
Greenberg Traurig's Brad Kaufman: A Mentor of Resolute Impact

Updated Category News Views 219

A Milestone for Mentorship at Greenberg Traurig In the often cutthroat jungle of law, finding someone who actually gives a damn about you is as rare as finding a unicorn. Yet, there it is—Brad Kaufman, at the helm of Greenberg Traurig's professional development, proving that mentorship can be more than just a checkbox on a quarterly review. Award for Exceptional...

Continue Reading
Purdue's xGTT: Pioneering a New Trust Standard in Tech

Updated Category News Views 150

A Bold New Benchmark in Tech Trust You've got to hand it to the folks at Purdue's Krach Institute—they're not dancing around the fringes but diving straight into the thick of it with their Global Trusted Tech Standard, or xGTT. This isn't just another checkbox for compliance nerds. The xGTT is all about building trust in technology that's woven with democratic values...

Continue Reading

Top 5 Most Recently Viewed Articles

HawkEye 360 Expands Capabilities with Strategic NRO Partnership

Updated Category News Views 189

HawkEye 360's New Partnership with the NRO HawkEye 360, recognized as a leader in sharing signals intelligence data and analytics, has recently secured a significant funding extension from the National Reconnaissance Office (NRO) alongside the Commercial Systems Program Office (CSPO). This collaborative effort is set to span over 23 months, aiming to enhance the...

Continue Reading
Consumer Sentiment and Its Impact on Economic Reflation Trends

Updated Category News Views 88

Understanding Consumer Sentiment Trends In recent discussions, we have explored how indicators like inflation gauges can influence economic forecasts. A notable aspect is consumer sentiment, which provides insights into spending behaviors and overall market confidence. Recent readings suggest a surprising optimism among consumers, especially in light of complex inflation...

Continue Reading
Ocular Therapeutix Announces Major Stock Offering Ahead of Trials

Updated Category News Views 264

Ocular Therapeutix's Strategic Stock Offering Announcement Ocular Therapeutix, Inc. (Nasdaq: OCUL), known for its commitment to enhancing retinal health, has declared an exciting new chapter in its journey. The company has recently confirmed the pricing for an underwritten public offering of 37,909,018 shares of its common stock, set at $12.53 per share. This significant...

Continue Reading
Roku Ads Manager: Innovations for Today’s Marketing Landscape

Updated Category News Views 145

Roku Unveils Ads Manager for Growth-Driven Marketers Roku (NASDAQ: ROKU) has stepped up its game in the streaming industry by launching a new platform named Roku Ads Manager. This self-service tool is tailored specifically for marketers eager to improve their connected television (CTV) campaigns. The rollout of this innovative platform comes as advertising trends shift...

Continue Reading
Evaxion Secures $10.8 Million in Strategic Public Offering

Updated Category News Views 97

Evaxion Biotech's Recent Public Offering Evaxion Biotech A/S (NASDAQ: EVAX) has recently made headlines with its announcement of a public offering. The company, renowned for its pioneering work in AI-Immunology™, has set the offering's combined public price at $2.71 per ADS, with warrants allowing the purchase of equal representation. This promising move emphasizes...

Continue Reading